Changeflow GovPing Healthcare & Life Sciences Subclinical Atherosclerosis in Juvenile Systemi...
Routine Notice Added Final

Subclinical Atherosclerosis in Juvenile Systemic Lupus Erythematosus

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

A new observational study (NCT07545408) registered on ClinicalTrials.gov will evaluate subclinical atherosclerosis in children and adolescents with juvenile systemic lupus erythematosus (SLE) by measuring carotid intima-media thickness (CIMT), and will assess associations with both traditional cardiovascular risk factors (dyslipidemia, hypertension, obesity) and non-traditional disease-related risk factors (disease activity, lupus nephritis, corticosteroid dose, disease duration). The study is listed as observational with an anticipated end date.

“The aim of this study is to evaluate subclinical atherosclerosis in children and adolescents with juvenile SLE by measuring carotid intima-media thickness (CIMT), and to determine its associations with traditional cardiovascular risk factors (dyslipidemia, hypertension, obesity) and non-traditional disease-related risk factors (disease activity, lupus nephritis, corticosteroid dose, disease duration).”

NIH , verbatim from source
Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 686 changes logged to date.

What changed

A new observational clinical trial registration was published on ClinicalTrials.gov for a study investigating subclinical atherosclerosis in juvenile systemic lupus erythematosus (SLE) patients. The study will measure carotid intima-media thickness (CIMT) as a marker of early atherosclerosis and will examine associations with traditional cardiovascular risk factors including dyslipidemia, hypertension, and obesity, as well as disease-specific factors such as disease activity, lupus nephritis, corticosteroid dose, and disease duration.

Affected parties include clinical investigators in pediatric rheumatology and cardiovascular epidemiology, as well as patients with juvenile SLE who may be eligible for enrollment. The study does not create compliance obligations but may inform future clinical guidance on cardiovascular risk monitoring in this patient population.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Subclinical Atherosclerosis in Juvenile Systemic Lupus Erythematosus

Observational NCT07545408 Kind: OBSERVATIONAL Apr 22, 2026

Abstract

The aim of this study is to evaluate subclinical atherosclerosis in children and adolescents with juvenile SLE by measuring carotid intima-media thickness (CIMT), and to determine its associations with traditional cardiovascular risk factors (dyslipidemia, hypertension, obesity) and non-traditional disease-related risk factors (disease activity, lupus nephritis, corticosteroid dose, disease duration).

Conditions: Atherosclerosis

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 22nd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Healthcare providers Clinical investigators Patients
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Observational study Cardiovascular risk assessment
Geographic scope
United States US

Taxonomy

Primary area
Public Health
Operational domain
Clinical Operations
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!